Clinical Trial Update: A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 study evaluating the combination of Azenosertib (ZN-c3) and Niraparib in platinum-resistant ova…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinoma
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Azenosertib (ZN-c3) (azenosertib)
• Niraparib (Niraparib)

Snippet

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Conditions: Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED